Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 26, 2017
Pharmacy Choice - News - Generic Drugs - September 26, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 75     Next >>     Go To Page:

9/25/17 - Alvogen Subsidiary Confirms ANDA Filing and Patent Challenge for Generic Revlimid
By a News Reporter-Staff News Editor at Pharma Business Week Alvogen subsidiary, Lotus Pharmaceuticals, announced that Celgene filed a suit on 6 September 2017 in the United States District Court for the District of New Jersey. The lawsuit was filed under provisions of the Hatch-Waxman Act, resulting in a stay of final Food and Drug Administratio
9/25/17 - Amphastar Announces Approval for Neostigmine Methylsulfate Injection, USP
Amphastar Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration granted approval of its abbreviated new drug application for Neostigmine Methylsulfate Injection, USP, 1 mg/mL, 10 mL, and 0.5 mg/mL, 10 mL vial. Amphastar s newly approved product was determined by the FDA to be therapeutically equivalent to Bloxiverz sol
9/25/17 - Cancer immunotherapy may get a boost by disabling specific T cells
By a News Reporter-Staff News Editor at Cancer Vaccine Week New York, NY Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests. That's a remarkable improvement over previous therapie
9/25/17 - Corporate Whistleblower Center Now Urges a Drug Company Insider to Call Them About Potentially Huge Rewards If They Have Proof Their Employer Is...
By a News Reporter-Staff News Editor at Managed Care Weekly Digest The Corporate Whistleblower Center says, "We are urging a pharmaceutical company manager or sales representative to call us anytime at 800-714-0303 if they have proof their employer is overbilling Medicare or Medicaid. Whistleblowers exactly like this will receive approximately $3
9/25/17 - FDA Approves Amgen And Allergan's MVASI bevacizumab-awwb For The Treatment Of Five Types Of Cancer
By a News Reporter-Staff News Editor at Clinical Trials Week Amgen and Allergan plc. announced that the U.S. Food and Drug Administration has approved MVASI? for all eligible indications of the reference product, Avastin . "The approval of MVASI marks a significant milestone for healthcare practitioners and patients as the first anti-cancer
9/25/17 - Global Biologics and Biosimilars Market 2017 Regional Analysis, Industry Demand, Trends, Size, Share, Forecast 2022
Market Research Explore : GlobalBiologics and BiosimilarsMarket Research Report 2017 offers a comprehensive study on Biologics and Biosimilars Industry including the current Biologics and Biosimilars market trends and market statu...
9/25/17 - Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista? NDA
In its CRL, the FDA provided certain recommendations and requests for information, including that Intellipharmaceutics complete the relevant Category 2 and Category 3 studies to assess the abuse-deterrent properties of Oxycodone ER by the oral and nasal routes of administration. Isa Odidi, CEO of Intellipharmaceutics. We had already planned the.
9/25/17 - Lupin receives USFDA approval for generic Clobex Lotion [India Infoline News Service]
Lupin announced that it has received final approval for its Clobetasol Propionate Lotion, 0.05% from the United States Food and Drug Administration Lupin announced that it has received final approval for its Clobetasol Propionate Lotion, 0.05% from the United States Food and Drug Administration to market a generic version of Clobex Lotion, 0.05%, t
9/25/17 - New Biosimilars Findings from Erasmus University Medical Center Outlined (The process defines the product: what really matters in biosimilar design...
New Biosimilars Findings from Erasmus University Medical Center Outlined. According to news reporting out of Rotterdam, Netherlands, by NewsRx editors, research stated, "Biologic drugs are highly complex molecules produced by living cells through a multistep manufacturing process. Our news journalists obtained a quote from the research from Erasmus
9/25/17 - Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of Exalgo 32mg Extended Release Tablets
Release date- 22092017- DUBLIN- Perrigo Company plc today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Exalgo 32 mg extended release tablets. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by
9/25/17 - Physicians' Education Resource Launches Inaugural European Webcast
By a News Reporter-Staff News Editor at Clinical Trials Week Physicians' Education Resource , LLC, the leading resource for oncology and hematology continuing medical education, will produce its first livestream European webcast, "Advent of Oncology Monoclonal Antibody Biosimilars- A European Perspective" on October 27, 2017, at 2:00 p.m. GMT.
9/25/17 - Reports Summarize Managed Care Findings from J.P. MacEwan and Co-Authors (What Do Pharmaceuticals Really Cost in the Long Run?)
By a News Reporter-Staff News Editor at Pharma Business Week Data detailed on Managed Care have been presented. According to news reporting from Los Angeles, California, by NewsRx journalists, research stated, "To estimate the long-run average cost for a typical drug, accounting for the effects of generic competition and medical cost offsets.
9/25/17 - Strides Shasun receives USFDA Approval for Omega-3-Acid Ethyl Esters capsules
Release date- 22092017- Bangalore- Strides Shasun Limited today announced that it has received approval from the United States Food& Drug Administration for Omega 3 Acid Ethyl Esters Softgel capsules, a generic version of Lovaza. The product to be manufactured in its flagship facility in Bangalore will be launched immediately. Strides Shasun, liste
9/25/17 - Sun Pharma Odomzo New Label Approval
Release date- 22092017- Mumbai- Sun Pharmaceutical Industries Ltd. today announced that one of its wholly owned subsidiaries has received approval from the US Food and Drug Administration for a new label for Odomzo, an oral hedgehog inhibitor indicated for the treatment of patients with locally advanced basal cell carcinoma that has recurred follow
9/25/17 - Teva Announces Reintroduction of Generic Depo-Provera in the United States
Teva Pharmaceutical Industries Ltd., today announced the reintroduction of the generic equivalent to Depo-Provera 1 Contraceptive Injection 150 mg/mL, in the United States. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file...
9/25/17 - Teva Names Kare Schultz as President and Chief Executive Officer
Mr. Schultz will succeed Dr. Yitzhak Peterburg, who will continue to serve as Interim Chief Executive Officer until Mr. Schultz joins the Company. Mr. Schultz will be relocating to Israel and based out of the Company's Petah Tikva headquarters.
9/24/17 - EDITORIAL: Drugs plan welcome [Business Daily (Kenya)]
The current high cost of the life-prolonging drugs has been blamed for slowing down efforts to tackle the disease in Africa. Reports that manufacturers of generic Aids drugs are set to start producing pills for Africa containing state of the art medicine that is used in the West is welcome news for the continent. READ: Kenyans are first in Africa t
9/23/17 - Glenmark charts out new path for growth [Syrian Arab News Agency]
Glenmark, one of the top ten Indian drug companies, has unveiled a blue print for next decade growth with new business strategies and focus areas, considering the pressures and transformation happening in the global generic drug scene. The Rs 9,185 crore turnover Glenmark, one of the pioneering Indian drug companies to take up new drug research as
9/23/17 - Oncology Biosimilars Market to reach US$17,478.2 mn by 2025, globally: Transparency Market Research [CPI Financial]
-Demand for Affordable Therapies for Cancer Aids Growth. Majorly fuelling the growth of oncology biosimilars market is the need to develop affordable therapies for the treatment of cancer. At this pace, the market that stood at US $2,100 mn in 2016 will become US $17,478.2 mn by the end of 2025..
9/22/17 - Amerigen believes that it is a first applicant to file an Abbreviated New Drug Application "ANDA" for certain strengths of Namzaric containing a...
By a News Reporter-Staff News Editor at Drug Week Amerigen Pharmaceuticals Limited announced that, based on the August 7th, 2017 update to the U.S. Food& Drug Administration's online databasea, the Company believes that it is a first applicant to file an Abbreviated New Drug Application for Namzaric 7/ 10 b and 21/ 10 c containing a "Paragraph
9/22/17 - ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL
By a News Reporter-Staff News Editor at Drug Week ANI Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL. The current annual U.S. market for this product is approximately $14.5 million, according
9/22/17 - Biosimilars take center stage at 2017 ACR/ARHP Annual Meeting
By a News Reporter-Staff News Editor at Drug Week ATLANTA- "Biosimilars: To Switch or Not to Switch?" Jonathan Kay, Professor of Medicine at the University of Massachusetts, and Dr. Roy Fleischmann, Clinical Professor at the University of Texas Southwestern Medical Center.
9/22/17 - Daily Technical Summary Reports on Generic Drugs Stocks Adamas Pharma, Eagle Pharma, Neos Therapeutics, and Zynerba Pharma
In today's pre-market research, research reports have been issued by DailyStockTracker.com on Adamas Pharmaceuticals Inc., Eagle Pharmaceuticals Inc., Neos Therapeutics Inc., and Zynerba Pharmaceuticals Inc.. On Thursday, shares in Emeryville, California headquartered Adamas Pharmaceuticals Inc. recorded a trading volume of 472,994 shares.
9/22/17 - India to make HIV/Aids drugs for Africa [BusinessReport (South Africa)]
JOHANNESURG- Makers of generic HIV/Aids drugs will start churning out millions of pills for Africa containing a state-of-the-art medicine widely used in rich countries. In return the drugmakers, India- based Mylan Laboratories and Aurobindo Pharma, will agree on the maximum price of about $75 a patient for a year s supply. The Bill& Melinda Gate
9/22/17 - Lannett Receives Approval For Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg And 40 mg
By a News Reporter-Staff News Editor at Drug Week Lannett Company, Inc. announced that it received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg, the therapeutic equivalent to the reference listed drug, Nexium Delayed-Release Cap
Articles(s): 1 - 25 of 75     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415